Skip to content

An investigation on the effect and potential anti-neuroinflammation mechanism of electro-acupuncture add-on treatment in patients with Parkinson’s disease

An investigation on the effect and potential anti-neuroinflammation mechanism of electro-acupuncture add-on treatment in patients with Parkinson’s disease

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14004293
Enrollment
Unknown
Registered
2014-02-14
Start date
2010-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson’s disease

Interventions

drug plus electro-acupuncture group:routine drug treatment and electro-acupuncture
drug alone group:routine drug treatment

Sponsors

Beijing Tiantan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. PD patients diagnosed with PD according to UK Parkinsons Disease Society Brain Bank: (1) At least existing two main symptoms of the following: rest tremor, bradykinesia, rigidity, postural instability; (2) Excluding patients with secondary Parkinson syndromes caused by history of drug exposure, repeated strokes, definite encephalitis and head injury,and with Parkinson plus syndromes, such as PSP, MSA, SND; (3) Having Excellent response to levodopa; (4) Persistent asymmetry affecting side of onset most; 2. Patients with sane, have good compliance and could cooperate with follow-up; 3. Signed informed consent himself (herself) or his (her) immediate family member.

Exclusion criteria

Exclusion criteria: (1) Essential tremor(ET); (2) Secondary Parkinson syndromes caused by history of repeated strokespoisoning, definite encephalitis and head injury; (3) Parkinson plus syndromes including PSP, MSA, DLB, etc.; (4) Severe dementia, dysarthria and other psychiatric diseases effecting expression; (5) Malignant tumor, inflammatory diseases, disability and other serious somatic disease; (6) Poor treatment compliance or difficult to follow-up, such as living too afar without contact.

Design outcomes

Primary

MeasureTime frame
Scales of motor symptoms;Scales of non-motor symptoms;Quality of life;Neurotransmitter;Neuroinflammatory factor;

Countries

China

Contacts

Public ContactWei ZHANG

Beijing Tiantan Hospital, Capital Medical University

ttyyzw@163.com+86 13911996107

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026